Relvène

Relvène is a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for rare pulmonary vascular diseases. The company's lead candidate, RLN-101, is a proprietary inhaled formulation of imatinib, a tyrosine kinase inhibitor targeting the platelet-derived growth factor receptor (PDGFR) pathway. RLN-101 is currently being advanced into a global registrational Phase 3 clinical trial for the treatment of Pulmonary Arterial Hypertension (PAH). By utilizing a dry powder inhaler for targeted delivery, Relvène seeks to improve the benefit-risk profile of imatinib by achieving high local concentrations in the pulmonary vasculature while reducing systemic exposure. The company is headquartered in San Mateo, California, and is led by a team of industry veterans with extensive experience in respiratory medicine.